| Crystal structure of CHK1 kinase domain in complex with a CLASPIN phosphopeptide | |
Heteromer
Q9HAW4; | 2-271 | 99.63 | 1×STU; 3×EDO; 1×ZN; |
|
| Structure of CHK1 10-pt. mutant complex with staurosporine | | monomer | 3-283 | 96.34 | 1×STU; 1×CL; |
|
| Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thio… | | monomer | 2-281 | 100 | 1×SO4; 1×YDI; |
|
| Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration | | monomer | 2-281 | 100 | 1×X8D; 2×SO4; |
|
| Crystal structure of Chk1 in complex with inhibitor S25 | | monomer | 2-280 | 100.0 | 1×SO4; 1×S25; |
|
| Crystal Structure of Chek1 in Complex with Inhibitor 1a | | monomer | 2-280 | 100.0 | 1×582; |
|
| crystal structure of chek1 in complex with inhibitor 22 | | monomer | 2-280 | 100.0 | 1×306; |
|
| Crystal structure of Chk1 in complex with inhibitor S01 | | monomer | 2-280 | 100.0 | 1×SO4; 1×07S; |
|
| crystal structure of Chek1 in complex with inhibitor 20 | | monomer | 2-280 | 100.0 | 1×710; |
|
| Crystal Structure of Chek1 in Complex with Inhibitor 54 | | monomer | 2-280 | 100.0 | 1×M54; |
|
| Crystal Structure of the CHK1 | | monomer | 2-280 | 100.0 | 1×H6K; 1×SO4; 1×GOL; 2×IPA; |
|
| crystal structure of Chek1 in complex with inhibitor 2a | | monomer | 2-280 | 100.0 | 1×7CS; |
|
| Crystal Structure of the CHK1 | | monomer | 2-280 | 100.0 | 1×H4K; 1×SO4; |
|
| Crystal Structure of the CHK1 | | monomer | 2-280 | 100.0 | 1×H1K; 1×SO4; 1×GOL; 4×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×1HK; 1×SO4; 2×GOL; 2×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK0; 2×SO4; 2×GOL; 1×IPA; |
|
| CHK1 kinase domain in complex with diarylpyrazine compound 1 | | monomer | 3-280 | 100.0 | 1×3DL; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×7HK; 1×SO4; 2×GOL; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 99.63 | 1×A58; 1×SO4; 1×IPA; |
|
| CHK1 kinase domain in complex with aminopyrazine compound 13 | | monomer | 3-280 | 100.0 | 1×3DV; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×H3K; 1×SO4; 1×GOL; 2×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK9; 1×SO4; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK6; 1×SO4; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×H9K; 1×SO4; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK1; 1×SO4; 1×GOL; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK7; 1×SO4; 1×GOL; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×6HK; 1×SO4; 3×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK8; 1×SO4; 2×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HK3; 1×SO4; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×H5K; 1×SO4; 1×GOL; 2×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×H2K; 1×SO4; 1×GOL; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×HKC; 1×SO4; |
|
| Crystal Structure of the CHK1 | | monomer | 3-280 | 100.0 | 1×H0K; 1×SO4; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-279 | 100.0 | 1×H7K; 1×SO4; 1×GOL; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-279 | 100.0 | 1×H8K; 1×SO4; 2×IPA; |
|
| THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1 | | monomer | 2-276 | 100.0 | 1×SO4; |
|
| Crystal Structure of Chk1 Complexed with a Hymenaldisine Analog | | monomer | 2-276 | 100.0 | 1×SO4; 1×HYM; |
|
| crystal structure of Chek1 in complex with inhibitor 1 | | monomer | 2-276 | 100.0 | 1×422; |
|
| crystal structure of Chek1 in complex with inhibitor 2 | | monomer | 2-276 | 100.0 | 1×373; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 2-276 | 100.0 | 1×PFP; 2×SO4; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 2-276 | 100.0 | 1×PFQ; 1×SO4; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 2-276 | 100.0 | 1×DF2; |
|
| 4-(Aminoalkylamino)-3-Benzimidazole-Quinolinones As Potent CHK1 Inhibitors | | monomer | 1-273 | 100.0 | 2×SO4; 1×12C; |
|
| X-RAY Crystal structure of compound 40 bound to human chk1 kinase domain | | monomer | 3-274 | 100.0 | 3×GOL; 1×1AO; |
|
| Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verif… | | monomer | 2-273 | 100.0 | 1×IDZ; 1×SO4; |
|
| Co-crystal structure of Checkpoint Kinase Chk1 with a pyrrolo-pyridine inhibitor | | monomer | 3-273 | 99.63 | 1×SO4; 1×199; |
|
| CHK1 kinase domain in complex with diazacarbazole compound 14 | | monomer | 3-273 | 100.0 | 1×3DW; |
|
| Characterization of the Chk1 allosteric inhibitor binding site | | monomer | 2-272 | 100.0 | 1×AGX; |
|
| The Complex Structure Of Checkpoint Kinase Chk1/SB218078 | | monomer | 3-273 | 100.0 | 1×SO4; 1×UCM; |
|
| The Complex Structure Of Checkpoint Kinase Chk1/Staurosporine | | monomer | 3-273 | 100.0 | 1×SO4; 1×STU; |
|
| CHK1 kinase domain with diazacarbazole compound 8: N-[3-(6-cyano-9H-pyrrolo[2,3-b:5,4-c']dipyridin-… | | monomer | 3-273 | 100.0 | 1×3XK; |
|
| CHK1 kinase domain with diazacarbazole compound 7: 3-(2-hydroxyphenyl)-9H-pyrrolo[2,3-b:5,4-c']dipy… | | monomer | 3-273 | 100.0 | 1×3XL; |
|
| CHK1 kinase domain with diazacarbazole compound 19 | | monomer | 3-273 | 100.0 | 1×3X7; |
|
| Characterization of the Chk1 allosteric inhibitor binding site | | monomer | 2-272 | 100.0 | 1×AGY; |
|
| CHK1 kinase domain in complex with diazacarbazole GNE-783 | | monomer | 3-273 | 100.0 | 1×3DX; |
|
| The Complex Structure Of Checkpoint Kinase Chk1/UCN-01 | | monomer | 3-273 | 100.0 | 1×SO4; 1×UCN; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 6-276 | 100.0 | 1×DF1; |
|
| X-ray crystal structure of compound 1 bound to human CHK1 kinase domain | | monomer | 3-272 | 100.0 | 1×C73; 3×GOL; |
|
| Crystal structure of CHK1 kinase domain in complex with ATPyS | | monomer | 2-271 | 99.63 | 1×AGS; 2×MG; 4×EDO; |
|
| Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors | | monomer | 2-270 | 100 | 7×GOL; 1×YEX; 1×SO4; |
|
| X-ray crystal structure of compound 70 bound to human CHK1 kinase domain | | monomer | 4-272 | 100.0 | 1×C70; |
|
| X-ray crystal structure of compound 22k bound to human Chk1 kinase domain | | monomer | 4-272 | 100.0 | 1×22K; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 09 | | monomer | 3-271 | 96.18 | 1×BWI; 4×EDO; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 06 | | monomer | 3-271 | 96.18 | 1×BVI; 4×EDO; |
|
| Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor | | monomer | 3-271 | 96.17 | 1×A3K; 1×CL; |
|
| CHK1 KINASE IN COMPLEX WITH COMPOUND 13 | | monomer | 2-270 | 100 | 1×SO4; 1×D4Q; |
|
| X-ray crystal structure of compound 17r bound to human Chk1 kinase domain | | monomer | 4-272 | 100.0 | 1×MI5; 3×GOL; |
|
| X-RAY Crystal structure of compound 39 bound to human chk1 kinase domain | | monomer | 4-272 | 100.0 | 1×1AM; |
|
| CHK1 KINASE IN COMPLEX WITH COMPOUND 13 | | monomer | 2-270 | 100 | 1×D4Z; 1×SO4; |
|
| X-RAY Crystal structure of compound 22a (R)-2-(4-chlorophenyl)-8-(piperidin-3-ylamino)imidazo[1,2-c… | | monomer | 4-272 | 100.0 | 1×1KO; |
|
| Structure of h-CHK1 complexed with A780125 | | monomer | 2-270 | 100 | 1×A25; |
|
| Crystal Structure of the CHK1 | | monomer | 3-271 | 100.0 | 1×2HK; 1×SO4; 2×GOL; 1×IPA; |
|
| Structure of h-CHK1 complexed with AA582939 | | monomer | 2-270 | 100 | 1×A58; |
|
| Crystal Structure of the CHK1 | | monomer | 3-271 | 100.0 | 1×3HK; 1×SO4; 2×GOL; 1×IPA; |
|
| Crystal Structure of the CHK1 | | monomer | 3-271 | 100.0 | 1×5HK; 1×SO4; 1×GOL; 1×IPA; |
|
| Structure of h-CHK1 complexed with A767085 | | monomer | 2-270 | 100 | 1×76A; |
|
| Structure of h-CHK1 complexed with A771129 | | monomer | 2-270 | 100 | 1×77A; |
|
| Crystal Structure of CHK1 with a Urea Inhibitor | | monomer | 2-270 | 100 | 1×A42; |
|
| h-CHK1 complexed with A431994 | | monomer | 2-270 | 100 | 1×A53; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 indazole inhibitor compound 6 | | monomer | 4-271 | 96.12 | 1×A1AV4; 7×EDO; |
|
| Structure of CHK1 8-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor | | monomer | 3-270 | 96.98 | 1×4K4; 1×MES; |
|
| Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 25 | | monomer | 4-271 | 96.15 | 1×UU6; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 18 | | monomer | 4-271 | 96.2 | 1×YXD; |
|
| Structure of Compound 2 bound to the CHK1 10-point mutant | | monomer | 4-271 | 96.18 | 1×ZXH; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 8 | | monomer | 3-270 | 96.15 | 1×42C; 1×CL; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 9 | | monomer | 3-270 | 96.15 | 1×TVW; 1×CL; |
|
| Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors | | monomer | 2-269 | 100 | 1×TQ1; 1×SO4; 6×EDO; |
|
| Structure of Compound 5 bound to the CHK1 10-point mutant | | monomer | 4-271 | 96.18 | 1×ZXL; |
|
| Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thio… | | monomer | 3-270 | 100.0 | 1×SO4; 5×GOL; 1×YDK; |
|
| Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor | | monomer | 3-270 | 96.17 | 1×A3H; |
|
| Crystal Structure of the CHK1 | | monomer | 3-270 | 100.0 | 1×HK4; 1×SO4; 2×GOL; 2×IPA; |
|
| Structure of CHK1 10-pt. mutant complex with arylbenzamide LRRK2 inhibitor | | monomer | 4-271 | 96.2 | 1×A0Q; 2×CL; |
|
| Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration | | monomer | 2-269 | 100.0 | 1×X8I; 2×SO4; 1×GOL; |
|
| Structure of h-CHK1 complexed with A859017 | | monomer | 2-269 | 100 | 1×85A; |
|
| Structure of CHK1 10-pt. mutant complex with pyrrolopyridine LRRK2 inhibitor | | monomer | 3-270 | 96.12 | 1×A3Q; |
|
| Structure of CHK1 10-pt. mutant complex with aminopyrimidine LRRK2 inhibitor | | monomer | 3-270 | 96.14 | 1×A0T; |
|
| Crystal Structure of the CHK1 | | monomer | 3-270 | 100.0 | 1×4HK; 1×IPA; 1×SO4; 1×GOL; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 3 | | monomer | 3-270 | 96.2 | 1×TVT; 2×CL; |
|
| Crystal Structure of the CHK1 | | monomer | 4-271 | 99.61 | 1×HK5; 1×SO4; 1×GOL; 1×IPA; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 22 | | monomer | 4-271 | 96.18 | 1×L80; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 7-274 | 100.0 | 1×DFZ; |
|
| Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening | | monomer | 6-273 | 100.0 | 1×3D3; |
|
| Crystal Structure of CHK1 with an Indol Inhibitor | | monomer | 2-269 | 100 | 1×43A; |
|
| Structure of CHK1 10-pt. mutant complex with indazole LRRK2 inhibitor | | monomer | 5-271 | 96.18 | 1×A1N; 2×CL; |
|
| X-ray crystal structure of compound 2a bound to human CHK1 kinase domain | | monomer | 6-272 | 100.0 | 1×C72; 3×GOL; |
|
| Structure of CHK1 10-pt. mutant complex with AMP-PNP | | monomer | 5-271 | 96.17 | 1×ANP; |
|
| Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor | | monomer | 4-270 | 96.17 | 1×A1K; 1×CL; 1×NA; |
|
| Crystal structure of CHK1-10pt-mutant complex with adenine | | monomer | 4-270 | 96.14 | 1×ADE; 1×CL; |
|
| Structure of CHK1 10-pt. mutant complex with pyrrolopyrimidine LRRK2 inhibitor | | monomer | 4-270 | 96.14 | 1×3FE; 1×CL; |
|
| Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((mo… | | monomer | 5-271 | 100.0 | 2×5UY; 4×EDO; 2×GOL; |
|
| Structure of CHK1 10-pt. mutant complex with aminopyridine LRRK2 inhibitor | | monomer | 4-270 | 96.12 | 1×A3E; |
|
| Structure of CHK1 12-pt. mutant complex with arylbenzamide LRRK2 inhibitor | | monomer | 4-270 | 95.4 | 1×A0Q; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 44 | | monomer | 5-271 | 96.17 | 1×U0K; 2×CL; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 45 | | monomer | 5-271 | 96.17 | 1×U0T; 2×CL; |
|
| Structure of CHK1 10-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor | | monomer | 4-270 | 96.15 | 1×4K4; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 13 | | monomer | 5-271 | 96.11 | 1×TWK; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 4-270 | 100.0 | 1×4YM; 3×EDO; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 4-270 | 100.0 | 1×4UB; 4×EDO; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 15 | | monomer | 4-270 | 96.17 | 1×BXI; |
|
| Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening | | monomer | 6-272 | 100.0 | 1×3B3; |
|
| X-ray crystal structure of compound 1 bound to human CHK1 kinase domain | | monomer | 7-272 | 100.0 | 1×09H; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 18 | | monomer | 5-270 | 96.11 | 1×TWH; |
|
| Novel kinase profile highlights the temporal basis of context dependent checkpoint pathways to cell… | | monomer | 6-271 | 100.0 | 1×5BE; |
|
| Structure of CHK1 12-pt. mutant complex with aminopyrimido-benzodiazepinone LRRK2 inhibitor | | monomer | 5-270 | 95.33 | 1×4K4; 1×CL; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 6-271 | 100.0 | 1×DFW; |
|
| Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening | | monomer | 6-271 | 100.0 | 1×3C3; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 10 | | monomer | 5-270 | 96.09 | 1×TW2; |
|
| Identification of chemically diverse Chk1 inhibitors by receptor- based virtual screening | | monomer | 6-271 | 100.0 | 1×3A3; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-271 | 100.0 | 2×YM7; 4×EDO; |
|
| Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verif… | | monomer | 6-270 | 100.0 | 1×DBQ; 1×SO3; |
|
| Identification of Novel, in vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design | | monomer | 6-270 | 100.0 | 1×5CV; 1×SO4; |
|
| Crystal structure of CHK1 complex with compound 9 | | monomer | 7-271 | 100.0 | 1×TVW; |
|
| Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verif… | | monomer | 6-270 | 100.0 | 1×ABO; |
|
| Crystal structure of CHK1 complex with adenine | | monomer | 7-271 | 100.0 | 1×ADE; 1×SO4; |
|
| Structure of LRRK2-CHK1 10-pt. mutant complex with heteroaryl-1H-indazole LRRK2 inhibitor 14 | | monomer | 8-271 | 96.12 | 1×UUF; |
|
| Structure of Compound 13 bound to the CHK1 10-point mutant | | monomer | 8-271 | 96.12 | 1×ZXP; |
|
| Crystal structure of chk1 kinase in complex with inhibitor 38 | | monomer | 7-270 | 100.0 | 1×38M; 2×SO4; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 32 | | monomer | 8-271 | 96.11 | 1×U0N; 2×CL; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-270 | 100.0 | 1×ZYV; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-270 | 100.0 | 1×YM6; 5×EDO; |
|
| Structure of CHK1 8-pt. mutant complex with arylbenzamide LRRK2 inhibitor | | monomer | 8-271 | 96.91 | 1×A0Q; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-270 | 100.0 | 1×XEZ; 6×EDO; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-270 | 100.0 | 1×ZYR; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-270 | 100.0 | 1×ZYS; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 6-269 | 100.0 | 1×YVQ; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 8-270 | 100.0 | 1×YM3; 5×EDO; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 8-270 | 100.0 | 1×YM5; 1×EDO; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 8-270 | 100.0 | 1×YM8; 9×EDO; |
|
| Structure-based Design of Novel Chk1 Inhibitors: Insights into Hydrogen Bonding and Protein-Ligand … | | monomer | 7-269 | 100.0 | 1×DFY; |
|
| Structure of CHK1 10-pt. mutant complex with LRRK2 inhibitor 24 | | monomer | 9-271 | 96.09 | 1×BYL; |
|
| Crystal structure of CHK1-10pt-mutant complex with compound 26 | | monomer | 8-270 | 96.08 | 1×U0Q; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-269 | 100.0 | 1×ZYW; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-269 | 100.0 | 1×ZY6; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 7-269 | 100.0 | 1×ZYQ; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 8-270 | 100.0 | 1×ZYT; |
|
| Discovery of Checkpoint Kinase Inhibitor AZD7762 by Structure Based Design and Optimization of Thio… | | monomer | 8-269 | 100.0 | 1×YDJ; 1×PO4; |
|
| Discovery of a Novel Class of triazolones as Checkpoint Kinase Inhibitors - Hit to Lead Exploration | | monomer | 9-270 | 100.0 | 1×X8E; 2×SO4; |
|
| Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors | | monomer | 9-270 | 100.0 | 1×ZYU; |
|
| CHK1 KINASE IN COMPLEX WITH COMPOUND 44 | | monomer | 9-269 | 100.0 | 1×D58; 1×SO4; |
|
| Crystal structure of the KA1 domain from human Chk1 | | monomer | 377-468 | 100 | 2×ACT; 1×GOL; |
|